Introduction
Occult primary melanoma (OPM) is defined as histologically confirmed subcutaneous, nodal or visceral metastatic melanoma with no known cutaneous, mucosal or ocular primary lesion [1] . About 4% (2%-16%) of all patients with malignant melanomas present in this way [1] [2] [3] [4] [5] [6] [7] . New South Wales has a high incidence of melanoma [8] . The Sydney Melanoma Unit is a tertiary referral unit which treats approximately 800 new cases of melanoma per year.
Several theories attempt to explain the occurrence of OPM. The less favoured theory is that cells arise de novo within lymph nodes perhaps because ectopic melanocytes undergo malignant transformation [2, 5, 9, 10] . The more widely accepted theory is that an undetected primary melanoma may have undergone spontaneous regression [1] , presumably as the result of a host immune response [5, 11] , but only after it has metastasised. If this were so, patients with OPM might retain an immune response to their metastatic deposits which would tend to prolong their survival in comparison to patients with known primary melanoma (KPM) and a similar metastatic pattern. Existing survival data on OPM refer mainly to patients first presenting only with lymph node metastases, but Reintgen et al. [1] compared all OPM patients, including patients with visceral metastases, with a control group of KPM to assess relative survival.
Previous studies have examined patients with lymph node or subcutaneous metastases from an occult primary source. In such patients, it is difficult to be certain whether the metastases may have arisen through regional lymphatic spread from a presumed primary, or were truly haematogenous distant metastases. In contrast, patients with visceral metastases can more safely be assumed to have haematogenous metastatic spread. The relatively large database of the Sydney Melanoma Unit included sufficient patients with visceral metastases from OPM to allow a specific study of this group. The present study was therefore focussed exclusively on such patients, using a retrospective matched cohort survival design. We wished to compare the survival rate of OPM versus KPM, measured from the time of presentation of visceral metastases.
Patients and methods

Identification of patients with visceral metastases from OPM
Since the establishment of the Sydney Melanoma Unit (SMU) database on melanoma patients first presenting in 1960. approximately 14343 patients have been recorded. Patients with metastases from OPM represented 4% of all patients recorded during that period. Any suggestion of a primary lesion was investigated prior to database registration as having an occult primary. This review was limited to OPM patients diagnosed between 1983-1996, who developed metastases in one or more visceral sites. A control group consisted of patients with known primary lesions and a similar distribution of metastases, recorded during the same period. For the purpose of survival comparisons, the observation period began at the date of diagnosis of the first viscera! metastases in both groups. Patients were excluded if on review they had metastases confined to bone (eight patients), subcutaneous (six) or lymph node sites (one), and those with multiple primary melanomas (three) or a final diagnosis other than melanoma (three). This left 146 eligible OPM patients with visceral metastases. Among these, 65 had presented earlier with non-visceral metastases (lymph node 53, skin or subcutaneous 35, bone two) prior to the diagnosis of visceral metastases, while 81 presented with visceral metastases at their initial diagnosis Patients with OPM were matched 1: 1 with similar KPM patients.
Matching procedure
Potential matching patients were extracted from the SMU database and their data were verified from original source data. Each OPM patient was matched within strata defined by age group (by decade at the time of visceral diagnosis), sex and dominant site. In previous analyses of the survival of patients with metastatic melanoma at the Sydney Melanoma Unit we have noted an independent adverse prognostic significance of metastases in brain and liver, more so than for those in other visceral sites [12] . In order to ensure the best possible matching in the present study we therefore assigned potentially matching patients from groups which ensured that the patients with OPM whose "worst" visceral metastatic site (in this hierarchy) was brain or liver were matched from KPM patients who had similar metastases (brain, liver or 'other' visceral metastases), by selecting one control patient from among those matching each OPM patient, using a table of random numbers.
Follow-up
Date of death or current vital status was ascertained for all patients up to 1 April 1996, except for one (0.3%) in the OPM group and three (1%) in the KPM group, who were analysed as alive at their last contact, one, 13, 37 and 58 months earlier. In the OPM group 132 patients (90%) were known to have died, compared with 129 (88%) in the KPM group.
Statistical methods
Survival was calculated from the date of diagnosis of visceral metastases to the date of death or last follow-up. Survival curves were prepared using the Kaplan-Meier procedure and compared using the logrank test [13] . Multivariate survival analysis used the proportional hazards model [14] to allow for the variables listed in Table I . All calculations used the SPIDA statistical package [15] . and all /'-values are two-sided.
Results
Descriptive statistics
The patients with OPM ranged in age from 17 to 84 years with a median age of 55 (interquartile range 42-65). The KPM age range was from 22 to 86 with a median age of 56 (interquartile range 42-65). There were 106 males and 40 females in both the occult and control groups (Table la) .
Median survival for the OPM group was 233 days (7.7 months), compared to 176 days (5.8 months) for KPM {P = 0.024, log-rank test. Figure 1) . 
Multivariate survival analysis
Two main models were considered. In the first, allowance was made for all patient characteristics recorded at the time of diagnosis of visceral metastases (Table la) , while in the second treatment modalities used after the diagnosis of visceral metastases (Table lb) were also included. Both models indicated an independent favourable prognosis for OPM as compared to KPM ( Table 2) . The corrected relative risks were 0.72 (95% CI: 0.55-0.93) without allowance for treatment and 0.74 (0.57-0.97) with allowance for treatment. Metastases to bone and to most visceral sites carried independent adverse prognostic significance (Table 2) . Among the treatment variables, surgical resection, either complete (HR: 0.3; 95% CI: 0.2-0.4) or partial (HR: 0.6; 95% CI: 0.4-0.8) was most strongly associated with superior survival (Table 2) . In these models, the number of metastatic sites was not an independent predictive factor.
Propoiton a5ve
Number at Risk 146 146 Figure 1 . Survival from date of diagnosis of visceral metastases.
Discussion
Patients with visceral metastases from an occult primary melanoma (OPM) survived significantly longer than a matched control group. One limitation of the present study design is that it is only partially randomised. It is of course impossible to randomise patients as to the nature of their primary site. The matched comparison attempts to be the next best design in providing control patients as similar as possible to the study group. However, due to the nature of the records available, we were able to match only for the presence or absence of metastases at a site rather than their size or total bulk. To some extent this would be offset by the random selection among available potential controls for each OPM patient. Despite the prognostic significance of number of metastatic sites seen in other series [16] , the number of organs involved with metastases did not add independent prognostic information in the present series. A possible lead time bias might arise because patients with KPM were under closer medical surveillance, and might therefore be diagnosed as having visceral metastases at a relatively earlier stage of disease evolution. However, some OPM patients (those who had presented with earlier subcutaneous, lymph node or bone metastases) were also under medical care before the diagnosis of visceral metastases. Moreover, any such bias remaining should be towards a survival benefit for the KPM patients, while in fact the opposite was found.
The survival duration in the present study is similar to that described by others [17, 18] , but their patients were specifically selected by entry into clinical trials, and thus may not be comparable with the present consecutive series.
Although treatment after diagnosis of metastases may affect survival, and there were small and statistically nonsignificant treatment differences between OPM and KPM groups, we found that the survival difference between the two groups remained significant after adjusting for treatment, and was only slightly smaller in magnitude. This suggests that the difference in survival between the OPM patients and KPM patients was not explained by surgery or palliative radiotherapy, but rather is due to an intrinsic biological difference between OPM and KPM.
One explanation for this [3] suggests that survival in OPM is relatively good because of innate immunity associated with the destruction of the unknown primary lesion. Maurer et al. [19] identified a circulating factor in a patient with regressing malignant melanoma that potentiated lymphocyte cytotoxic activity. Sumner and Foraker [20] observed that serum from a patient who The referent group for each site is having no metastases at that site. That is, brain metastases, for example above, has a HR of 2.5 compared to having no brain metastases. a 0.72 = ratio of survival of patients with a known primary (KPM) compared to those with occult primary (OPM).
had experienced a spontaneous regression of metastatic malignant melanoma may have induced regression when transferred to another patient. However, Giuliano et al. [21] , were unable to detect any difference in cellular immune response between patients with a known or occult primary lesion by dinitrochlorobenzene skin testing. Some investigators, however, have suggested that the level of antitumour immunity actually falls with the occurrence of metastases [21] .
Further evidence that immune responses may affect the natural history of malignant melanoma is provided by the phenomenon of spontaneous regression, in which established lymph node metastases occasionally disappear [1, 22] .
It has also been suggested that melanoma may originate as a primary tumour in the lymph nodes from melanocytes which migrated in the lymphatics from a benign naevus [1] . Kopf et al. [23] also suggest that a cutaneous primary melanoma may have been destroyed by trauma; that it exists but is indistinguishable from other lesions; the melanoma is too small or too deep to be recognised; or that it originated in an internal organ like the gastrointestinal tract, or adrenal gland. Thus the tumour may have been overlooked because of its benign appearance or location at a hidden site. Finally Lopes et al. [24] suggested that since during embryogenesis melanocytes migrate from the neuroectoderm into sites other than skin, they may undergo malignant transformation in those sites giving rise to apparently metastatic malignant melanoma.
Although the mechanism of OPM remains uncertain, the present observation of superior prognosis may have implications both for patient counselling and for the understanding of the biology of the disease.
